214 related articles for article (PubMed ID: 35935910)
1. Performance of multi-parametric magnetic resonance imaging through PIRADS scoring system in biopsy naïve patients with suspicious prostate cancer.
Nowier A; Mazhar H; Salah R; Shabayek M
Arab J Urol; 2022; 20(3):121-125. PubMed ID: 35935910
[TBL] [Abstract][Full Text] [Related]
2. Comparison of prostate cancer detection rates between magnetic resonance imaging-targeted biopsy and transrectal ultrasound-guided biopsy according to Prostate Imaging Reporting and Data System in patients with PSA ≥4 ng/mL: a systematic review and meta-analysis.
Zhu K; Qin Z; Xue J; Miao C; Tian Y; Liu S; Zhu S; Gu Q; Hou C; Xu A; Yang J; Wang Z
Transl Androl Urol; 2019 Dec; 8(6):741-753. PubMed ID: 32038971
[TBL] [Abstract][Full Text] [Related]
3. Assessing the validity of Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) scoring system in diagnosis of peripheral zone prostate cancer.
Dola EF; Nakhla OL; Genidi EA
Eur J Radiol Open; 2017; 4():19-26. PubMed ID: 28377946
[TBL] [Abstract][Full Text] [Related]
4. Multiparametric MRI in detection and staging of prostate cancer.
Boesen L
Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
[TBL] [Abstract][Full Text] [Related]
5. Assessment of elastographic Q-analysis score combined with Prostate Imaging-Reporting and Data System (PI-RADS) based on transrectal ultrasound (TRUS)/multi-parameter magnetic resonance imaging (MP-MRI) fusion-guided biopsy in differentiating benign and malignant prostate.
Tian H; Ding Z; Wu H; Yang K; Song D; Xu J; Dong F
Quant Imaging Med Surg; 2022 Jul; 12(7):3569-3579. PubMed ID: 35782253
[TBL] [Abstract][Full Text] [Related]
6. Early experience with multiparametric magnetic resonance imaging-targeted biopsies under visual transrectal ultrasound guidance in patients suspicious for prostate cancer undergoing repeated biopsy.
Boesen L; Noergaard N; Chabanova E; Logager V; Balslev I; Mikines K; Thomsen HS
Scand J Urol; 2015 Feb; 49(1):25-34. PubMed ID: 24922550
[TBL] [Abstract][Full Text] [Related]
7. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
8. Multiparametric magnetic resonance imaging - Transrectal ultrasound-guided cognitive fusion biopsy of the prostate: Clinically significant cancer detection rates stratified by the Prostate Imaging and Data Reporting System version 2 assessment category.
John S; Cooper S; Breau RH; Flood TA; Cagiannos I; Lavallee LT; Morash C; O'sullivan J; Schieda N
Can Urol Assoc J; 2018 Dec; 12(12):401-406. PubMed ID: 29940139
[TBL] [Abstract][Full Text] [Related]
9. Targeted MRI/TRUS fusion-guided biopsy in men with previous prostate biopsies using a novel registration software and multiparametric MRI PI-RADS scores: first results.
Tewes S; Hueper K; Hartung D; Imkamp F; Herrmann TR; Weidemann J; Renckly S; Kuczyk MA; Wacker F; Peters I
World J Urol; 2015 Nov; 33(11):1707-14. PubMed ID: 25774003
[TBL] [Abstract][Full Text] [Related]
10. Can a prostate biopsy be safely deferred on PI-RADS 1,2 or 3 lesions seen on pre-biopsy mp-MRI?
Abdul Raheem R; Razzaq A; Beraud V; Menzies-Wilson R; Odeh R; Ibiok I; Mulawkar P; Andrews H; Anjum I; Hosny K; Leslie T
Arab J Urol; 2023; 21(1):10-17. PubMed ID: 36818375
[TBL] [Abstract][Full Text] [Related]
11. Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative.
Faiella E; Santucci D; Greco F; Frauenfelder G; Giacobbe V; Muto G; Zobel BB; Grasso RF
Radiol Med; 2018 Feb; 123(2):143-152. PubMed ID: 29019021
[TBL] [Abstract][Full Text] [Related]
12. Prospective nonrandomized study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy to magnetic resonance imaging with subsequent MRI-guided biopsy in biopsy-naïve patients.
Castellucci R; Linares Quevedo AI; Sánchez Gómez FJ; Díez Rodríguez J; Cogorno L; Cogollos Acuña I; Salmerón Béliz I; Muñoz Fernández de Legaría M; Martínez Piñeiro L
Minerva Urol Nefrol; 2017 Dec; 69(6):589-595. PubMed ID: 29094851
[TBL] [Abstract][Full Text] [Related]
13. Impact of changing PI-RADS cutoff on prostate cancer detection by MRI cognitive fusion biopsy in biopsy-naïve patients.
El-Helaly HA; Mahmoud AA; Magdy AM; Hasehem A; Ibrahim HM; Mohamed KM; Ismail MH
J Egypt Natl Canc Inst; 2023 Mar; 35(1):5. PubMed ID: 36872409
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
Lim CS; Abreu-Gomez J; Carrion I; Schieda N
AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
[No Abstract] [Full Text] [Related]
15. Combining targeted and systematic prostate biopsy improves prostate cancer detection and correlation with the whole mount histopathology in biopsy naïve and previous negative biopsy patients.
Mischinger J; Schöllnast H; Zurl H; Geyer M; Fischereder K; Adelsmayr G; Igrec J; Fritz G; Merdzo-Hörmann M; Elstner J; Schmid J; Triebl A; Trimmel V; Reiter C; Steiner J; Rosenlechner D; Seles M; Pichler GP; Pichler M; Riedl J; Schöpfer-Schwab S; Strobl J; Hutterer GC; Zigeuner R; Pummer K; Augustin H; Ahyai S; Mannweiler S; Fuchsjäger M; Talakic E
Front Surg; 2022; 9():1013389. PubMed ID: 36277287
[TBL] [Abstract][Full Text] [Related]
16. The value of magnetic resonance imaging-ultrasound fusion targeted biopsies for clinical decision-making among patients with previously negative transrectal ultrasound biopsy and persistent prostate-specific antigen elevation.
Gillis CJ; Southall TM; Wilson R; Anderson M; Young J; Hewitt R; Andrews M
Can Urol Assoc J; 2022 Jun; 16(6):E315-E320. PubMed ID: 35099383
[TBL] [Abstract][Full Text] [Related]
17. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial.
Tonttila PP; Lantto J; Pääkkö E; Piippo U; Kauppila S; Lammentausta E; Ohtonen P; Vaarala MH
Eur Urol; 2016 Mar; 69(3):419-25. PubMed ID: 26033153
[TBL] [Abstract][Full Text] [Related]
18. Multiparametric Prostate MRI in Biopsy-Naïve Men: A Prospective Evaluation of Performance and Biopsy Strategies.
Krüger-Stokke B; Bertilsson H; Langørgen S; Sjøbakk TAE; Bathen TF; Selnæs KM
Front Oncol; 2021; 11():745657. PubMed ID: 34722302
[TBL] [Abstract][Full Text] [Related]
19. Multiparametric Magnetic Resonance Imaging in Evaluation of Clinically Significant Prostate Cancer.
Ingole SM; Mehta RU; Kazi ZN; Bhuyar RV
Indian J Radiol Imaging; 2021 Jan; 31(1):65-77. PubMed ID: 34316113
[No Abstract] [Full Text] [Related]
20. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
[No Abstract] [Full Text] [Related]
[Next] [New Search]
